Science drives oncology new product development and the AACR special conferences are always a good place to look for insights into where the field is both emerging and also going in the future.
At the recent AACR Tumor Immunology and Immunotherapy conference, several presentations stood out for us as being noteworthy for either building on an existing story or the new perspectives they offered, some of which involved new targets we’d not heard before.
In this post, we take a take at some of the data presented, how it builds upon what we already know, and possible directions it may take us in. After all, the best way to predict the future is to invent it.
It’s time to shine some light on novel targets, biomarkers, and emerging combination approaches…